GlucoMe signs Abbott, J&J veteran to lead North American team

TEL AVIV, Israel — Digital diabetes management platform GlucoMe on Thursday named John Erickson to the role of EVP, general manager North America. In this role, John will be responsible for leading the company's business development, business management, marketing and sales in the territory.



"We are thrilled to have John as part of the team," stated Yiftah Ben Aharon, GlucoMe CEO. "We have the opportunity to forever change the way diabetes is managed and treated across the country and around the world, and with his proven achievements and experience, John will be an invaluable asset in helping us advance our mission."



"Diabetes management and care are major concerns for tens of millions of American patients, as well as healthcare payers and professionals," Erickson said. "GlucoMe's digital technology and strategic roadmap are opening up an exciting avenue to enable simpler and more effective diabetes care resulting in better outcomes. I look forward to working closely with the entire team as GlucoMe takes its next steps forward."



Erickson previously served as divisional VP at Abbott Labs, where he was responsible for all diabetes products and strategy direction. He held global commercial responsibilities at Johnson & Johnson as its director of international franchise development and director of business development, where he helped develop the company's first internal, cellular-based, biotechnology artificial pancreas program.



Erickson brings with him years of expertise as a strategic global healthcare business leader and most recently was president and CEO at RapidBio Systems.



GlucoMe is a connected diabetes care platform that simplifies the way patients, caregivers and medical professionals manage the disease, the company noted. It combines diabetes monitoring hardware, mobile software and big data cloud computing infrastructure.